Eli Lilly & Co has announced its agreement to purchase U.S. biotech firm Orna Therapeutics for up to $2.4 billion in cash. Bloomberg posted on X, highlighting this acquisition as part of Eli Lilly's strategic expansion in the biotech sector. The company, renowned for its weight-loss medication Zepbound, aims to enhance its portfolio with Orna's innovative RNA technology. This move reflects Eli Lilly's commitment to advancing its research and development capabilities in the field of biotechnology. The acquisition is expected to bolster Eli Lilly's position in the market, providing new opportunities for growth and innovation. The deal underscores the company's focus on expanding its therapeutic offerings and strengthening its presence in the biotech industry.